Cargando…
Case report: JAK1/2 inhibition with baricitinib in the treatment of STING-associated vasculopathy with onset in infancy
BACKGROUND: Gain-of-function mutations in STING1 (also known as TMEM173) which result in constitutive activation of STING, have been reported to cause STING-associated vasculopathy with onset in infancy (SAVI). Although a wider spectrum of associated manifestations and perturbations in disease onset...
Autores principales: | Wu, Jianqiang, Zhou, Qing, Zhou, Hua, Lu, Meiping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601276/ https://www.ncbi.nlm.nih.gov/pubmed/37884945 http://dx.doi.org/10.1186/s12969-023-00916-6 |
Ejemplares similares
-
Lung Inflammation in STING-Associated Vasculopathy with Onset in Infancy (SAVI)
por: David, Clémence, et al.
Publicado: (2022) -
Use of Tofacitinib for infant-onset STING-associated vasculopathy: A case report from China
por: Shen, Danping, et al.
Publicado: (2022) -
Treatment of STING-associated vasculopathy with onset in infancy in patients carrying a novel mutation in the TMEM173 gene with the JAK3-inhibitor tofacitinib
por: Tokgun, Pervin Elvan, et al.
Publicado: (2023) -
STING-associated vasculopathy with onset in infancy: a familial case series report and literature review
por: Wang, Yan, et al.
Publicado: (2021) -
A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI)
por: Lin, Bin, et al.
Publicado: (2020)